2025 Third Quarter Report
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Securities code: 600812 Securities abbreviation: North China Pharmaceutical
North China Pharmaceutical Co., Ltd.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The company's board of directors, board of supervisors and directors, supervisors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the general manager, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) guarantee that the financial information in the quarterly report is true, accurate and complete.
Whether the third quarter financial statements have been audited
□Yes √No
1. Main financial data
(1) Main accounting data and financial indicators
Unit: Yuan Currency: RMB This reporting period increased from the beginning of the reporting period to the same period last year. Items at the end compared with the same period last year During this reporting period From the beginning of the reporting period to the end of the reporting period
Decrease the range of change Increase or decrease the range of change
(%) (%) Operating income 2,209,790,846.44 -5.12 7,484,828,636.64 -1.00 Total profit 73,179,311.17 0.29 287,215,555.62 28.81 Attributable to shareholders of listed companies
35,006,615.86 14.85 158,504,018.75 54.69Net profit
Attributable to shareholders of listed companies
Net profit after deducting non-recurring gains and losses 23,377,819.31 -17.12 143,324,253.00 73.61
1/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
cash flow from operating activities
169,947,821.43 -3.00 661,445,878.34 -37.50 Net amount
Basic earnings per share (yuan/share) 0.020 11.11 0.092 53.33 Diluted earnings per share (yuan/share) 0.020 11.11 0.092 53.33 Weighted average return on equity increased by 0.079 increased by 0.987
0.650 2.898
(%) Percentage point Percentage point Increase or decrease at the end of this reporting period compared to the end of this reporting period The end of the previous year The end of the previous year
Change (%) Total assets 21,537,284,924.56 21,471,458,316.43 0.31 Attributable to shareholders of listed companies
5,505,224,974.65 5,389,402,984.11 2.15 Owners’ equity
Note: "This reporting period" refers to the three-month period from the beginning of this quarter to the end of this quarter, the same below.
(2) Non-recurring profit and loss items and amounts
√Applicable □Not applicable
Unit: Yuan Currency: RMB from the beginning of the year to the end of the reporting period
Non-recurring profit and loss items Current period amount Description
Amount
Gains and losses on disposal of non-current assets, including accrued
769,564.07 759,717.40
Offset portion of asset impairment provision
Government subsidies included in the current profit and loss, but with the company
Closely related to normal business operations and in compliance with national policies
Policy provisions, enjoyment according to determined standards, public 11,943,130.63 14,696,725.13
Except for government subsidies that have a lasting impact on the company’s profits and losses
Outside
Impairment of receivables subject to separate impairment test
474,000.00 1,098,000.00
Prepare to transfer back
Gains and losses from debt restructuring 211,092.00
Other non-operating income other than the above items
48,787.99 311,343.26
and expenses
Less: Income tax impact 1,435,578.91 1,477,751.79
Amount of impact on minority shareholders’ equity (after tax) 171,107.24 419,360.25
Total 11,628,796.54 15,179,765.75
If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained.
□Applicable √Not applicable
(3) Changes in major accounting data and financial indicators and reasons
√Applicable □Not applicable
2/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Project name Change ratio (%) Main reasons
Net profit attributable to shareholders of listed companies_
54.69
From the beginning of the year to the end of the reporting period, the company further deepened comprehensive budget control, implemented lean management, and took measures to improve quality and efficiency after non-economic improvements, which all belong to the shareholders of the listed company, reduce procurement costs and various expenses, and improve profitability.
End of term
Net cash flow from operating activities_
-37.50 The company received land compensation in the same period last year.
From the beginning of the year to the end of the reporting period
Basic earnings per share (yuan/share)_year-to-date report
53.33
The end of the reporting period is mainly due to the increase in net profit attributable to shareholders of listed companies from the beginning to the end of the reporting period (diluted earnings per share (yuan/share)) from the beginning of the year to the end of the reporting period compared with the same period.
53.33
end of reporting period
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Share
Total number of preference shareholders whose voting rights were restored at the end of the reporting period
Total number of ordinary shareholders at the end of the reporting period 88,011 0 (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Staking, marking or freezing status
Shareholding Ratio Holding Restricted Coupons
Name of shareholder Nature of shareholder Number of shares held
Example (%) Number of shares
shares
Quantity
Status
Jizhong Energy Co., Ltd. State-owned legal person 413,080,473 24.08 0 None 0North China Pharmaceutical Group Co., Ltd. State-owned legal person 341,471,645 19.90 0 Pledge 80,000,000Jizhong Energy Group Co., Ltd. State-owned legal person 189,146,698 11.02 0 None 0 Central Huijin Asset Management Co., Ltd.
State-owned legal person 54,916,601 3.20 0 None 0 company
Hong Kong Securities Clearing Company Limited Overseas legal person 20,053,068 1.17 0 None 0 Caida Securities Co., Ltd. State-owned legal person 13,200,000 0.77 0 None 0 Mao Nian’an Unknown 9,192,719 0.54 0 None 0 China Merchants Bank Co., Ltd.-Southern
Fang CSI 1000 Trading Open Index Others 7,844,700 0.46 0 None 0 Securities Investment Funds
Zhuang Xiaomin Unknown 4,800,000 0.28 0 None 0 China Merchants Bank Co., Ltd.-China
Xia CSI 1000 Trading Open-End Index Others 4,662,500 0.27 0 None 0 Securities Investment Funds
Shareholding status of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing)
Type and quantity of shares
Name of shareholder Number of shares held without selling restrictions
Share Type Quantity
3/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Jizhong Energy Co., Ltd. 413,080,473 RMB ordinary shares 413,080,473 North China Pharmaceutical Group Co., Ltd. 341,471,645 RMB ordinary shares 341,471,645 Jizhong Energy Group Co., Ltd. 189,146,698 RMB ordinary shares 189,146,698 Central Huijin Asset Management Co., Ltd.
54,916,601 RMB ordinary shares 54,916,601 Company
Hong Kong Securities Clearing Company Limited 20,053,068 RMB ordinary shares 20,053,068 Caida Securities Co., Ltd. 13,200,000 RMB ordinary shares 13,200,000 Mao Nian'an 9,192,719 RMB ordinary shares 9,192,719 China Merchants Bank Co., Ltd. - Nanjing
CSI 1000 Trading Open-End Index 7,844,700 RMB ordinary shares 7,844,700 Securities Investment Fund
Zhuang Xiaomin 4,800,000 RMB ordinary shares 4,800,000 China Merchants Bank Co., Ltd.-Hua
Xia CSI 1000 Trading Open-End Index 4,662,500 RMB ordinary shares 4,662,500 Digital Securities Investment Fund
North China Pharmaceutical Group Co., Ltd. is a wholly-owned subsidiary of Jizhong Energy Group Co., Ltd., the company’s controlling shareholder.
Capital subsidiary, Jizhong Energy Co., Ltd. is the controlling subsidiary of Jizhong Energy Group Co., Ltd. The above-mentioned shareholders are related or acting in concert
Division. Explanation of North China Pharmaceutical Group Co., Ltd., Jizhong Energy Co., Ltd. and the top ten other unlimited sales activities
The shareholders have no related relationships. The company does not know whether there are related relationships or are in the same industry among the other shareholders mentioned above.
Moving.
The top 10 shareholders and the top 10 are not allowed to sell
North China Pharmaceutical Group Co., Ltd. holds 195,471,645 shares through ordinary accounts, and shareholders participate in margin financing and securities lending and refinancing through credit accounts
Holds 146,000,000 shares.
Description of business situation (if any)
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable √Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable √Not applicable
3. Other reminders
Investors need to be reminded of other important information regarding the company’s operations during the reporting period.
□Applicable √Not applicable
4/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
4. Quarterly Financial Statements
(1) Types of audit opinions
□Applicable √Not applicable
(2) Financial statements
Consolidated Balance Sheet
September 30, 2025
Prepared by: North China Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Items September 30, 2025 Current assets on December 31, 2024:
Monetary funds 1,605,062,335.69 1,660,278,671.77 Settlement reserves
Loan funds
trading financial assets
Derivative financial assets
Notes receivable
Accounts receivable 2,422,540,197.37 2,049,376,568.87 Accounts receivable financing 350,394,389.11 242,448,937.63 Prepayments 207,259,110.33 213,219,933.01 Premium receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 1,407,547,938.60 1,436,372,128.81 Among them: interest receivable 3,264,682.40
Dividends receivable 60,000,000.00 Financial assets purchased under resale agreements
Inventory 2,253,265,923.69 2,510,534,823.14 Including: data resources
contract assets
Assets held for sale
Non-current assets due within one year
Other current assets 90,550,497.32 147,048,806.61
Total current assets 8,336,620,392.11 8,259,279,869.84 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
long-term receivables
Long-term equity investment 1,228,642,491.57 1,187,039,254.62 Other equity instrument investments 17,700,000.00 17,700,000.00
5/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Other non-current financial assets
investment real estate
Fixed assets 6,256,511,256.90 6,298,709,576.20 Construction in progress 378,116,789.56 381,136,756.29 Productive biological assets
oil and gas assets
Right-of-use assets 331,771,339.51 581,378,283.93 Intangible assets 2,846,843,592.12 2,755,997,485.79 Including: data resources
Development expenditure 2,009,743,438.68 1,851,668,702.51 Including: data resources
goodwill
Long-term deferred expenses 58,901,559.49 66,114,322.63 Deferred income tax assets 72,434,064.62 72,434,064.62 Other non-current assets
Total non-current assets 13,200,664,532.45 13,212,178,446.59
Total assets 21,537,284,924.56 21,471,458,316.43 Current liabilities:
Short-term borrowings 6,619,707,942.87 7,094,995,438.88 Borrowings from the central bank
borrowing funds
Trading financial liabilities
Derivative financial liabilities
Notes payable 391,107,979.20 451,196,780.05 Accounts payable 1,807,759,590.55 1,843,880,445.11 Advance payments
Contract liabilities 167,621,266.19 281,751,156.27 Financial assets sold and repurchased
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
Agent underwriting securities funds
Employee benefits payable 194,880,533.46 183,943,890.68 Taxes payable 55,729,751.74 40,657,143.51 Other payables 468,003,915.97 395,473,727.32 Including: interest payable 11,151,367.37 675,564.00
Dividends payable 385,687.50 385,687.50 Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 2,185,396,153.03 632,496,733.34 Other current liabilities 519,466,289.37 37,134,683.26 Total current liabilities 12,409,673,422.38 10,961,529,998.42
6/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Non-current liabilities:
insurance contract reserves
Long-term borrowings 2,181,118,000.00 3,458,920,560.64 Bonds payable
Among them: preferred shares
perpetual bond
Lease liabilities 149,772,417.70 263,531,519.71 Long-term payables 8,317,000.00 9,735,000.00 Long-term employee benefits payable
Estimated liabilities
Deferred income 85,271,762.15 74,024,417.65 Deferred income tax liabilities 29,103,732.43 29,103,732.43 Other non-current liabilities
Total non-current liabilities 2,453,582,912.28 3,835,315,230.43
Total liabilities 14,863,256,334.66 14,796,845,228.85 Owners’ equity (or shareholders’ equity):
Paid-in capital (or equity) 1,715,730,370.00 1,715,730,370.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 3,869,803,463.59 3,862,187,679.30 Less: treasury shares
Other comprehensive income 7,725,829.76 7,935,661.63 Special reserves 1,703,679.80 319,749.33 Surplus reserves 333,357,636.58 333,357,636.58 General risk reserves
Undistributed profits -423,096,005.08 -530,128,112.73 belong to the parent company’s owners’ equity (or shareholders’ rights
5,505,224,974.65 5,389,402,984.11 profit) total
Minority shareholders’ equity 1,168,803,615.25 1,285,210,103.47
Total owners’ equity (or shareholders’ equity) 6,674,028,589.90 6,674,613,087.58 Total liabilities and owners’ equity (or shareholders’ equity) 21,537,284,924.56 21,471,458,316.43 Chairman and general manager: Wang Lixin Chief accountant: Xiao Zhiguang Head of accounting department: Zhao Shihai
consolidated income statement
January-September 2025
Prepared by: North China Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited Projects for the first three quarters of 2025 and the first three quarters of 2024
(January-September) (January-September)
- Total operating income 7,484,828,636.64 7,560,235,670.39
7/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Including: operating income 7,484,828,636.64 7,560,235,670.39 interest income
Premiums earned
Fee and commission income
- Total operating costs 7,258,017,573.93 7,395,586,299.65 Including: operating costs 5,295,459,714.07 5,272,198,266.78 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
Reinsurance cost
Taxes and surcharges 81,610,453.98 77,366,304.85 Sales expenses 969,584,616.21 1,052,291,747.95 Management expenses 395,365,377.85 415,243,846.33 Research and development expenses 253,811,956.49 251,674,097.83Financial expenses 262,185,455.33 326,812,035.91Including: Interest expenses 276,486,185.63 345,915,986.61
Interest income 16,631,110.47 18,449,560.56 plus: other income 23,503,062.51 22,655,374.24 Investment income (losses are listed with "-") 42,102,545.14 33,415,822.41 Including: investments in associates and joint ventures
41,598,420.34 32,484,755.71 capital income
Financial instruments measured at amortized cost
Income from derecognition of assets
Exchange gains (losses are listed with "-")
Net exposure hedging income (losses are filled in with "-"
column)
Gains from changes in fair value (losses are marked with a “-”
Fill in the column)
Credit impairment loss (losses are listed with "-") -34,909,777.16 -6,417,154.90 Asset impairment losses (losses are listed with "-") 28,637,601.76 8,350,790.94 Asset disposal income (losses are listed with "-") 759,717.40 440,884.14
Operating profit (losses are listed with "-") 286,904,212.36 223,095,087.57 plus: non-operating income 1,067,182.69 3,339,164.23 minus: non-operating expenses 755,839.43 3,458,318.97
Total profits (total losses are listed with "-") 287,215,555.62 222,975,932.83 Less: income tax expenses 75,676,686.45 76,535,187.12
Net profit (net loss is listed with "-") 211,538,869.17 146,440,745.71
(1) Classification by business continuity
- Net profit from continuing operations (net loss is marked with "-" 211,538,869.17 146,440,745.71
8/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Fill in the column)
- Net profit from discontinued operations (net loss is marked with "-"
Fill in the column)
(2) Classification according to ownership ownership
- Net profit attributable to shareholders of the parent company (net
158,504,018.75 102,463,641.21 Losses are listed with a “-” sign)
- Profit and loss of minority shareholders (net loss is filled in with "-"
53,034,850.42 43,977,104.50 columns)
- Net after-tax amount of other comprehensive income -209,831.87 -150,201.56
(1) Other comprehensive income attributable to owners of the parent company
-209,831.87 -150,201.56 net profit after tax
- Other comprehensive income that cannot be reclassified into profit or loss
(1) Remeasurement of changes in defined benefit plan
(2) Other comprehensive assets that cannot be transferred to profit or loss under the equity method
combined income
(3) Changes in fair value of investments in other equity instruments
move
(4) Changes in the fair value of the enterprise’s own credit risk
move
- Other comprehensive income that will be reclassified into profit and loss -209,831.87 -150,201.56
(1) Other comprehensive convertible profits and losses under the equity method
income
(2) Changes in fair value of other debt investments
(3) Financial assets are reclassified into other comprehensive
Amount of income
(4) Credit impairment provisions for other debt investments
(5) Cash flow hedging reserve
(6) Translation difference of foreign currency financial statements -209,831.87 -150,201.56 (7) Others
(2) Other comprehensive income attributable to minority shareholders
net of tax
- Total comprehensive income 211,329,037.30 146,290,544.15
(1) Comprehensive income attributable to owners of the parent company
158,294,186.88 102,313,439.65 total
(2) Total comprehensive income attributable to minority shareholders 53,034,850.42 43,977,104.50
8. Earnings per share:
(1) Basic earnings per share (yuan/share) 0.0920 0.0600
(2) Diluted earnings per share (yuan/share) 0.0920 0.0600 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.
Chairman and General Manager: Wang Lixin Chief Accountant: Xiao Zhiguang Head of Accounting Department: Zhao Shihai
9/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Consolidated Cash Flow Statement
January-September 2025
Prepared by: North China Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited Projects for the first three quarters of 2025 and the first three quarters of 2024
(January-September) (January-September)
1. Cash flow generated from operating activities:
Cash received from selling goods and providing services 5,427,084,311.73 5,594,132,346.90 Net increase in customer deposits and deposits from banks
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions
Net increase in borrowing funds
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
Tax returns received 124,236,162.80 92,584,407.65 Other cash received related to operating activities 89,955,535.29 504,202,062.14
Subtotal of cash inflows from operating activities 5,641,276,009.82 6,190,918,816.69 Cash paid for purchasing goods and receiving services 2,616,723,420.80 2,604,852,414.66 Net increase in customer loans and advances
Net increase in deposits with central banks and inter-banks
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 960,271,911.27 977,258,465.26 Various taxes and fees paid 359,758,331.02 333,320,080.79 Cash paid for other operating activities 1,043,076,468.39 1,217,092,220.57 Subtotal cash outflow from operating activities 4,979,830,131.48 5,132,523,181.28
Net cash flow generated from operating activities 661,445,878.34 1,058,395,635.41
2. Cash flow generated from investing activities:
Recover cash received on investments
Cash received from investment income 60,293,032.80
Disposal of fixed assets, intangible assets and other long-term assets
303,200.00 1,256,500.00 Net cash received from property
Cash received from disposal of subsidiaries and other business units
net amount
10/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Other cash received related to investing activities
Subtotal of cash inflows from investing activities 60,596,232.80 1,256,500.00 Purchase and construction of fixed assets, intangible assets and other long-term assets
380,002,187.69 481,875,355.35 cash paid
Cash paid for investment 300,000,000.00
Net increase in mortgage loans
Receive cash payments from subsidiaries and other business units
net amount
Other cash payments related to investing activities
Subtotal of cash outflows from investing activities 680,002,187.69 481,875,355.35
Net cash flow generated from investing activities -619,405,954.89 -480,618,855.35
3. Cash flow generated from financing activities:
Cash received from investment 205,000,000.00 903,000,000.00 Including: Cash received by subsidiaries from investment from minority shareholders
- -Cash
Cash received from borrowings 5,835,360,000.00 7,635,095,000.00 Cash received from other financing activities 1,020,000,000.00 707,360,000.00
Subtotal of cash inflows from financing activities 7,060,360,000.00 9,245,455,000.00 Cash paid to repay debts 5,713,875,623.10 6,971,652,723.13 Cash paid to distribute dividends, profits or pay interest
391,711,985.74 391,688,722.05
Including: dividends paid by subsidiaries to minority shareholders,
66,830,370.96 39,743,666.67Profit
Other cash payments related to financing activities 1,087,423,793.36 1,602,772,467.48 Subtotal of cash outflows from financing activities 7,193,011,402.20 8,966,113,912.66
Net cash flow generated from financing activities -132,651,402.20 279,341,087.34
4. The impact of exchange rate changes on cash and cash equivalents
3,040,427.58 8,067,852.11
Net increase in cash and cash equivalents -87,571,051.17 865,185,719.51 Plus: opening balance of cash and cash equivalents 1,262,403,953.02 505,004,576.56
Balance of cash and cash equivalents at the end of the period 1,174,832,901.85 1,370,190,296.07 Chairman and General Manager: Wang Lixin Chief Accountant: Xiao Zhiguang Head of Accounting Department: Zhao Shihai
Parent company balance sheet
September 30, 2025
Prepared by: North China Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Items September 30, 2025 Current assets on December 31, 2024:
11/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Monetary funds 1,026,415,228.49 1,160,690,227.72 Trading financial assets
Derivative financial assets
Notes receivable
Accounts receivable 1,879,462,199.83 1,627,377,722.55 Accounts receivable financing 342,745,667.04 171,828,991.19 Prepayments 64,951,619.45 49,937,860.73 Other receivables 5,003,859,424.27 4,732,333,700.83 Including: interest receivable 8,425,255.46 3,264,682.40
Dividends receivable 28,166,333.77 76,325,142.88 Inventory 935,887,888.37 1,097,619,342.69 Including: data resources
contract assets
Assets held for sale
Non-current assets due within one year
Other current assets 1,010,817,154.96 1,011,191,211.51
Total current assets 10,264,139,182.41 9,850,979,057.22 Non-current assets:
debt investment
Other debt investments
long-term receivables
Long-term equity investment 5,154,005,518.77 5,107,407,180.39 Other equity instrument investments 17,700,000.00 17,700,000.00 Other non-current financial assets
investment real estate
Fixed assets 2,055,891,788.11 1,995,498,023.29 Construction in progress 63,904,123.50 134,159,717.73 Productive biological assets
oil and gas assets
Right-of-use assets 147,163,436.47 169,888,234.89 Intangible assets 1,687,546,934.17 1,702,703,651.89 Including: data resources
Development expenditure 1,347,286,964.54 1,360,357,450.97 Including: data resources
goodwill
Long-term deferred expenses 36,052,822.71 37,794,985.05 Deferred income tax assets 22,787,669.98 22,787,669.98 Other non-current assets
Total non-current assets 10,532,339,258.25 10,548,296,914.19
Total assets 20,796,478,440.66 20,399,275,971.41 Current liabilities:
Short-term borrowings 5,227,500,000.00 5,595,103,188.87
12/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Trading financial liabilities
Derivative financial liabilities
Notes payable 264,280,000.00 256,000,000.00 Accounts payable 1,242,418,903.07 1,109,560,112.89 Advance receipts
Contract liabilities 55,108,774.22 127,799,352.34 Employee benefits payable 76,617,623.62 71,813,445.78 Taxes payable 17,095,966.52 11,531,625.83 Other payables 2,452,748,722.24 2,807,507,534.20 of which: interest payable 8,641,563.99
Dividends payable
Liabilities held for sale
Non-current liabilities due within one year 1,812,534,319.52 480,852,648.43 Other current liabilities 510,292,364.82 19,186,116.56
Total current liabilities 11,658,596,674.01 10,479,354,024.90 Non-current liabilities:
Long-term borrowings 1,636,170,000.00 2,670,530,000.00 Bonds payable
Among them: preferred shares
perpetual bond
Lease liabilities 708,184.98 77,772,523.95 Long-term payables 200,000.00 200,000.00 Long-term employee benefits payable
Estimated liabilities
Deferred income 33,334,096.02 30,025,777.81 Deferred income tax liabilities
Other non-current liabilities
Total non-current liabilities 1,670,412,281.00 2,778,528,301.76
Total liabilities 13,329,008,955.01 13,257,882,326.66 Owners’ equity (or shareholders’ equity):
Paid-in capital (or equity) 1,715,730,370.00 1,715,730,370.00 Other equity instruments
Among them: preferred shares
perpetual bond
Capital reserve 4,056,523,492.19 4,053,523,492.19 Less: treasury shares
other comprehensive income
Special reserves 222,159.50 222,159.50 Surplus reserves 304,148,707.51 304,148,707.51 Undistributed profits 1,390,844,756.45 1,067,768,915.55
Total owners’ equity (or shareholders’ equity) 7,467,469,485.65 7,141,393,644.75 Total liabilities and owners’ equity (or shareholders’ equity) 20,796,478,440.66 20,399,275,971.41
13/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Chairman and General Manager: Wang Lixin Chief Accountant: Xiao Zhiguang Head of Accounting Department: Zhao Shihai
Parent company income statement
January-September 2025
Prepared by: North China Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited Projects for the first three quarters of 2025 and the first three quarters of 2024
(January-September) (January-September)
- Operating income 3,807,316,337.32 4,482,517,441.64 Less: Operating costs 3,071,673,731.93 3,706,444,780.50 Taxes and surcharges 37,381,486.05 37,766,648.19 Sales expenses 358,366,019.76 402,179,650.16 Administrative expenses 111,786,616.67 109,531,992.91 Research and development expenses 92,959,460.50 48,995,831.25 Financial expenses 182,234,019.56 233,231,171.64 Including: interest expense 216,954,461.36 282,426,241.69
Interest income 36,197,378.74 53,099,020.03 plus: other income 2,206,503.00 849,527.77 Investment income (losses are listed with "-") 417,753,298.62 194,929,394.56 Including: investments in associates and joint ventures
41,598,338.38 32,442,258.73 capital income
Financial assets measured at amortized cost
Derecognition of revenue
Net exposure hedging income (losses are filled in with "-"
column)
Gains from changes in fair value (losses indicated by “-”
(Fill in the number)
Credit impairment loss (losses are listed with "-") 218,345.39 -6,694,842.03 Asset impairment losses (losses are listed with "-") 1,099,258.48 5,807,763.69 Asset disposal income (losses are marked with "-"
52,967.00 276,614.02 columns)
Operating profit (losses are listed with "-") 374,245,375.34 139,535,825.00 plus: non-operating income 357,651.43 725,137.68 minus: non-operating expenses 55,274.77 1,452,419.10
Total profits (total losses are listed with "-") 374,547,752.00 138,808,543.58 Less: income tax expenses
Net profit (net loss is listed with "-") 374,547,752.00 138,808,543.58
(1) Net profit from continuing operations (net loss is represented by “-”
374,547,752.00 No. 138,808,543.58 (please fill in)
(2) Net profit from discontinued operations (net loss is represented by “-”
(Fill in the number)
5. Net amount of other comprehensive income after tax
14/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
(1) Other comprehensive income that cannot be reclassified into profit or loss
benefit
Remeasure the changes in defined benefit plan
Other comprehensive income that cannot be transferred to profit or loss under the equity method
benefit
Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk
(2) Other comprehensive income that will be reclassified into profit and loss
Other comprehensive income that can be converted to profit or loss under the equity method
Changes in fair value of other debt investments
Financial assets are reclassified and included in other comprehensive income
amount of
Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements
7.Others
- Total comprehensive income 374,547,752.00 138,808,543.58
7. Earnings per share:
(1) Basic earnings per share (yuan/share)
(2) Diluted earnings per share (yuan/share)
Chairman and General Manager: Wang Lixin Chief Accountant: Xiao Zhiguang Head of Accounting Department: Zhao Shihai
Parent company cash flow statement
January-September 2025
Prepared by: North China Pharmaceutical Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited Projects for the first three quarters of 2025 and the first three quarters of 2024
(January-September) (January-September)
1. Cash flow generated from operating activities:
Cash received from selling goods and providing services 2,532,493,124.48 2,521,612,702.67 Tax refunds received 16,591,190.20 38,189.45 Cash received from other operating activities 4,066,773,929.95 3,240,639,251.64
Subtotal of cash inflows from operating activities 6,615,858,244.63 5,762,290,143.76 Cash paid for purchasing goods and receiving services 1,323,085,576.68 1,494,905,515.53 Cash paid to and for employees 415,461,756.90 424,137,382.52 Various taxes paid 151,318,576.10 136,178,647.68 Other cash paid related to operating activities 4,645,116,363.46 2,621,472,585.80
Subtotal of cash outflows from operating activities 6,534,982,273.14 4,676,694,131.53 Net cash flow from operating activities 80,875,971.49 1,085,596,012.23
2. Cash flow generated from investing activities:
Recover cash received on investments
Cash received from investment income 424,176,469.35 19,365,734.42
15/16
North China Pharmaceutical Co., Ltd. 2025 Third Quarter Report
Disposal of fixed assets, intangible assets and other long-term assets
308,300.00 424,400.00 Net cash recovered from property
Disposal of cash received from subsidiaries and other business units
Net amount of money
Other cash received related to investing activities 254,780,612.30 663,480,612.30
Subtotal of cash inflows from investing activities 679,265,381.65 683,270,746.72 Purchase and construction of fixed assets, intangible assets and other long-term assets
81,819,802.84 103,296,724.47 Cash paid for the property
Cash paid for investment 5,000,000.00 3,023,546.10 Cash paid for acquisition of subsidiaries and other business units
Net amount of money
Other cash payments related to investing activities 319,070,612.30 663,480,612.30 Subtotal cash outflows from investing activities 405,890,415.14 769,800,882.87
Net cash flow generated from investing activities 273374966.51 -86530136.15
3. Cash flow generated from financing activities:
Cash received from investments 3,000,000.00 3,000,000.00 Cash received from borrowings 3,726,220,000.00 5,409,000,000.00 Cash received from other financing activities 600,000,000.00 414,790,000.00
Subtotal of cash inflows from financing activities 4,329,220,000.00 5,826,790,000.00 Cash paid to repay debts 4,050,020,000.00 4,685,850,000.00 Cash paid to distribute dividends, profits or pay interest 266,954,235.04 291,893,367.82 Other cash payments related to financing activities 1,034,901,700.44 1,333,993,598.58 Subtotal of cash outflows from financing activities 5,351,875,935.48 6,311,736,966.40
Net cash flow generated from financing activities -1,022,655,935.48 -484,946,966.40
Impact of exchange rate changes on cash and cash equivalents 3,341.89 749,965.74
Net increase in cash and cash equivalents -668,401,655.59 514,868,875.42 Plus: opening balance of cash and cash equivalents 870,536,884.08 188,014,728.72
Balance of cash and cash equivalents at the end of the period 202,135,228.49 702,883,604.14 Chairman and General Manager: Wang Lixin Chief Accountant: Xiao Zhiguang Head of Accounting Department: Zhao Shihai
The first implementation of new accounting standards or standard interpretations starting in 2025 will involve adjustments to the financial statements at the beginning of the year of first implementation.
□Applicable √Not applicable
Announcement is hereby made.
North China Pharmaceutical Co., Ltd. October 24, 2025
16/16